GlassScriptPhysician profile
Sergio R Flores
NPI 1588674022
$6,540.78
in general payments reported to CMS, 2019-2025
38 companies · $1,339 in 2025
The $1,339 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $907 · 2020: $248 · 2021: $384 · 2022: $923 · 2023: $1,203 · 2024: $1,537 · 2025: $1,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,078.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,518.08 | 2019-2025 | |
| Janssen Biotech, INC. | $732.22 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $719.58 | 2019-2025 | Entyvio, Eohilia, Vpriv |
| Pfizer INC. | $425.38 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $421.66 | 2019-2025 | Trulance, Xifaxan |
| Intercept Pharmaceuticals, INC. | $351.40 | 2019-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $349.08 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $259.54 | 2019-2025 | |
| Kuros Biosciences USA, INC | $215.10 | 2024 | Magnetos |
| Genzyme Corporation | $181.01 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $150.90 | 2019-2023 | Rebyota |
| Cook Medical LLC | $115.07 | 2019 | |
| Phathom Pharmaceuticals, INC. | $109.23 | 2023-2025 | Voquezna |
| Novo Nordisk INC | $89.29 | 2024 | |
| Qol Medical, LLC | $87.89 | 2019-2024 | Sucraid |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $87.57 | 2019-2025 | Suflave, Sutab |
| Lilly USA, LLC | $65.51 | 2024-2025 | Omvoh |
| Vivus LLC | $60.39 | 2023-2025 | Qsymia |
| Olympus America INC. | $55.36 | 2019 | |
| Ardelyx, INC. | $50.41 | 2023-2024 | Ibsrela |
| Alfasigma USA, INC. | $43.40 | 2020-2022 | |
| Shionogi INC | $39.57 | 2019 | |
| Ironwood Pharmaceuticals, INC | $39.06 | 2020-2023 | Linzess |
| Medtronic, INC. | $37.30 | 2023 | Pillcam |
| Stryker Corporation | $37.28 | 2025 | Aequalis Perform Reversed |
| Redhill Biopharma INC. | $33.91 | 2021-2024 | Talicia |
| Orphalan INC | $31.70 | 2024 | Cuvrior |
| Evoke Pharma, INC. | $27.77 | 2024 | |
| Ucb, INC. | $27.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.78 | 2023 | Cyltezo |
| Alcresta Therapeutics, INC. | $24.01 | 2023 | Relizorb |
| Merck Sharp & Dohme LLC | $20.80 | 2022 | |
| Madrigal Pharmaceuticals | $20.41 | 2025 | Rezdiffra |
| Nestle Healthcare Nutrition INC. | $20.16 | 2023 | |
| Celltrion USA INC. | $19.27 | 2024 | Vegzelma |
| Daiichi Sankyo INC. | $18.52 | 2019 | |
| Capsovision, INC. | $16.28 | 2025 | Capsocam Plus |
| Celgene Corporation | $13.89 | 2023 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergio Flores listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.